The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Publication|Articles|February 7, 2025
Targeted Therapies in HR+/HER2– Breast Cancer
Author(s)Oncology Live® Staff
Advertisement
KEY TAKEAWAYS
- A better understanding of endocrine therapy (ET) resistance mechanisms has guided the development of targeted combination therapies for HR-positive/HER2-negative (HR+/HER2–) breast cancer, but resistance evolution complicates long-term disease management.
- The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib have
become foundational in the first-line treatment of HR+/HER2– breast
cancer, significantly improving survival outcomes. - Emerging next-generation targeted therapies, such as capivasertib
and elacestrant, target resistance mechanisms like ESR1 mutations
and alterations in the PI3K/AKT/mTOR pathway. These biomarker driven
approaches are critical but require testing standardization
across institutions. - Antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, represent a paradigm shift in treating ET-refractory metastatic breast cancer, showing efficacy even in heavily pretreated populations.
- Despite improved outcomes with targeted therapies and their combinations, challenges remain regarding their optimal sequencing and rechallenge strategies post progression in the HR+/HER2– breast cancer treatment algorithm.
Advertisement
Related to this article
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1–positive, metastatic triple-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5